Anne-Marie Schmitt-Verhulst

List of Publications by Year
in descending order

70 papers	4,606 citations	168829 31 h-index	111975 67 g-index
70 all docs	70 docs citations	70 times ranked	4809 citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy. Cancers, 2019, 11, 1832.	1.7	38
2	Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nature Communications, 2017, 8, 1404.	5.8	177
3	Distinct patterns of cytolytic Tâ€cell activation by different tumour cells revealed by Ca²⁺ signalling and granule mobilization. Immunology, 2017, 150, 199-212.	2.0	3
4	Molecular profiling of <scp>CD</scp> 8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO Journal, 2015, 34, 2042-2058.	3.5	100
5	Control of <scp>CD</scp>8 T cell proliferation and terminal differentiation by active <scp>STAT</scp>5 and <scp>CDKN</scp>2A/<scp>CDKN</scp>2B. Immunology, 2015, 145, 543-557.	2.0	12
6	Visualization of granzyme Bâ€expressing <scp>CD</scp>8 T cells during primary and secondary immune responses to Listeria monocytogenes. Immunology, 2015, 145, 24-33.	2.0	10
7	IFNÎ³ producing CD8+T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas. OncoImmunology, 2015, 4, e974959.	2.1	19
8	Silence STAT3 in the procancer nicheâ€¦and activate CD8⁺ T cells to kill premetastatic myeloid intruders. European Journal of Immunology, 2015, 45, 44-48.	1.6	3
9	Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8⁺T-cell therapy. OncoImmunology, 2014, 3, e958951.	2.1	4
10	The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11115-11120.	3.3	79
11	Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred <scp>T</scp> cells?. Pigment Cell and Melanoma Research, 2013, 26, 167-175.	1.5	9
12	Active STAT5 Regulates T-bet and Eomesodermin Expression in CD8 T Cells and Imprints a T-betâ€“Dependent Tc1 Program with Repressed IL-6/TGF-Î²1 Signaling. Journal of Immunology, 2013, 191, 3712-3724.	0.4	49
13	Visualization of Cytolytic T Cell Differentiation and Granule Exocytosis with T Cells from Mice Expressing Active Fluorescent Granzyme B. PLoS ONE, 2013, 8, e67239.	1.1	22
14	Minimal Tolerance to a Tumor Antigen Encoded by a Cancer-Germline Gene. Journal of Immunology, 2012, 188, 111-121.	0.4	25
15	Activated STAT5 Promotes Long-Lived Cytotoxic CD8+ T Cells That Induce Regression of Autochthonous Melanoma. Cancer Research, 2012, 72, 76-87.	0.4	36
16	Epithelial-Mesenchymal-Transition-Like and TGFÎ² Pathways Associated with Autochthonous Inflammatory Melanoma Development in Mice. PLoS ONE, 2012, 7, e49419.	1.1	34
17	Granzyme Bâ€tdTomato, a new probe to visualize cytolytic effector cell activation. European Journal of Immunology, 2012, 42, 264-266.	1.6	4
18	Selection of Tâ€cell receptors with a recurrent CDR3Î² peptideâ€contact motif within the repertoire of alloreactive CD8⁺ T cells. European Journal of Immunology, 2011, 41, 2414-2423.	1.6	4

#	Article	IF	Citations
19	Disrupted Lymph Node and Splenic Stroma in Mice with Induced Inflammatory Melanomas Is Associated with Impaired Recruitment of T and Dendritic Cells. PLoS ONE, 2011, 6, e22639.	1.1	28
20	Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted Tâ€cell receptor diversity. Immunology, 2010, 129, 41-54.	2.0	36
21	Tumor-Initiated Inflammation Overrides Protective Adaptive Immunity in an Induced Melanoma Model in Mice. Cancer Research, 2010, 70, 3515-3525.	0.4	54
22	CD8 T Cell Help for Innate Antitumor Immunity. Journal of Immunology, 2007, 179, 6651-6662.	0.4	94
23	How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides?. EMBO Journal, 2007, 26, 1972-1983.	3.5	89
24	An Inducible Mouse Model of Melanoma Expressing a Defined Tumor Antigen. Cancer Research, 2006, 66, 3278-3286.	0.4	47
25	Distinct orientation of the alloreactive monoclonal CD8 T cell activation program by three different peptide/MHC complexes. European Journal of Immunology, 2006, 36, 1856-1866.	1.6	19
26	Temporal cross-talk between TCR and STAT signals for CD8 T cell effector differentiation. European Journal of Immunology, 2006, 36, 3090-3100.	1.6	23
27	STAT5-Mediated Signals Sustain a TCR-Initiated Gene Expression Program toward Differentiation of CD8 T Cell Effectors. Journal of Immunology, 2006, 176, 4834-4842.	0.4	72
28	Selective Defect in Antigen-Induced TCR Internalization at the Immune Synapse of CD8 T Cells Bearing the ZAP-70(Y292F) Mutation. Journal of Immunology, 2005, 175, 3140-3149.	0.4	24
29	Thymocyte-Intrinsic Genetic Factors Influence CD8 T Cell Lineage Commitment and Affect Selection of a Tumor-Reactive TCR. Journal of Immunology, 2004, 172, 5069-5077.	0.4	19
30	Structural and kinetic basis for low affinity cross-reactivity in T cell allorecognition. European Journal of Immunology, 2003, 33, 3060-3069.	1.6	12
31	Distinct Thresholds for CD8 T Cell Activation Lead to Functional Heterogeneity: CD8 T Cell Priming Can Occur Independently of Cell Division. Journal of Immunology, 2003, 170, 2442-2448.	0.4	49
32	Differential implication of protein kinase C isoforms in cytotoxic T lymphocyte degranulation and TCR-induced Fas ligand expression. International Immunology, 2003, 15, 1441-1450.	1.8	29
33	A T Cell Receptor CDR3Î² Loop Undergoes Conformational Changes of Unprecedented Magnitude Upon Binding to a Peptide/MHC Class I Complex. Immunity, 2002, 16, 345-354.	6.6	201
34	A novel reporter strain to follow Cre-mediated recombination in T and NK cells. Genesis, 2002, 32, 287-292.	0.8	6
35	Gene Profiling Approach to Establish the Molecular Bases for Partial versus Full Activation of NaÃ¯ve CD8 T Lymphocytes. Annals of the New York Academy of Sciences, 2002, 975, 68-76.	1.8	23
36	Regulation of Activator Protein-1 and NF-Î²B in CD8+ T Cells Exposed To Peripheral Self-Antigens. Journal of Immunology, 2001, 166, 4399-4407.	0.4	21

#	Article	IF	Citations
37	Identification of endogenous peptides recognized byin vivo orin vitro generated alloreactive cytotoxic T lymphocytes: distinct characteristics correlated with CD8 dependence. European Journal of Immunology, 2001, 31, 421-432.	1.6	48
38	Differential Survival of Transferred CD8 T Cells and Host Reconstitution Depending on TCR Avidity for Host-Expressed Alloantigen. Journal of Immunology, 2001, 166, 7200-7207.	0.4	11
39	Crystal structure of a T cell receptor bound to an allogeneic MHC molecule. Nature Immunology, 2000, 1, 291-297.	7.0	199
40	Antigen-induced TCRâ€“CD3 down-modulation does not require CD3Î´ or CD3Î³ cytoplasmic domains, necessary in response to anti-CD3 antibody. International Immunology, 1999, 11, 1731-1738.	1.8	18
41	Selection of phenotypically distinct NK1.1+ T cells upon antigen expression in the thymus or in the liver. European Journal of Immunology, 1999, 29, 2330-2343.	1.6	26
42	Developmental control of antigen-induced thymic transcription factors. International Immunology, 1996, 8, 1421-1428.	1.8	13
43	Regulation of interferon-Î³ mRNA in a cytolytic T cell clone: Ca2+-induced transcription followed by mRNA stabilization through activation of protein kinase C or increase in cAMP. European Journal of Immunology, 1995, 25, 889-895.	1.6	23
44	TCR-Associated Î¶-FcÏµRIÎ³ heterodimers on CD4â^'CD8â^' NK1.1+ t cells selected by specific class I MHC antigen. Immunity, 1995, 3, 427-438.	6.6	40
45	Tolerance induction by elimination of subsets of self-reactive thymocytes. International Immunology, 1994, 6, 1593-1604.	1.8	17
46	Tolerance induction as a multi-step process. European Journal of Immunology, 1994, 24, 285-293.	1.6	36
47	The degree of CD8 dependence of cytolytic T cell precursors is determined by the nature of the T cell receptor (TCR) and influences negative selection in TCR-transgenic mice. European Journal of Immunology, 1994, 24, 1572-1577.	1.6	44
48	The balance between deletion and activation of CD4+8+ thymocytes is controlled by T cell receptor-antigen interactions and is affected by cyclosporin A. European Journal of Immunology, 1994, 24, 2401-2409.	1.6	13
49	T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. European Journal of Immunology, 1994, 24, 2469-2476.	1.6	191
50	Transmembrane signalling through the T-cell-receptor-CD3 complex. Current Opinion in Immunology, 1993, 5, 324-333.	2.4	94
51	T cell activation and thymic tolerance induction require different adhesion intensities of the CD8 co-receptor. International Immunology, 1992, 4, 1169-1174.	1.8	19
52	Influence of antigen density on degree of clonal deletion in T cell receptor transgenic mice. International Immunology, 1992, 4, 541-547.	1.8	31
53	Threshold tolerance in H-2Kb-specific TCR transgenic mice expressing mutant H-2Kb: conversion of helper-independent to helper-dependent CTL. International Immunology, 1992, 4, 1419-1428.	1.8	25
54	Electroporation of CTL clones: a useful method to investigate signalling pathways leading to the expression of effector functions. Journal of Immunological Methods, 1992, 151, 107-115.	0.6	8

#	Article	IF	Citations
55	A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product. European Journal of Immunology, 1992, 22, 1651-1654.	1.6	38
56	Biochemical and functional association between CD8 and H-2 at the surface of a T cell clone. Molecular Immunology, 1991, 28, 827-837.	1.0	8
57	Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell, 1991, 65, 293-304.	13.5	509
58	T cell receptor/CD3 complex internalization following activation of a cytolytic T cell clone: Evidence for a protein kinase C-independent staurosporine-sensitive step. European Journal of Immunology, 1991, 21, 1623-1634.	1.6	55
59	Evidence for quantitative and qualitative differences in functional activation of MIs-reactive T cell clones and hybridomas by antigen or TcR/CD3 antibodies. European Journal of Immunology, 1991, 21, 2581-2589.	1.6	15
60	Each of the two productive T cell receptor Î±-gene rearrangements found in both the A10 and BM 3.3 T cell clones give rise to an Î± chain which can contribute to the constitution of a surface-expressed Î±Î² dimer. International Immunology, 1991, 3, 719-729.	1.8	57
61	Chapter 19 Positive and Negative Liposome-Based Immunoselection Techniques. Methods in Cell Biology, 1989, 32, 447-471.	0.5	0
62	Role of Ti/CD3, Thy-1, and Ly-6 in Cytolytic T-Cell Activation Analyzed with Ti Loss Variants. Annals of the New York Academy of Sciences, 1988, 532, 33-43.	1.8	3
63	Reconstitution of MHC class I specificity by transfer of the T cell receptor and Lyt-2 genes. Cell, 1987, 50, 545-554.	13.5	221
64	Pleiotropic loss of activation pathways in a T-cell receptor Î±-chain deletion variant of a cytolytic T-cell clone. Nature, 1987, 325, 628-631.	13.7	96
65	Direct evidence for chromosomal inversion during T-cell receptor Î²-gene rearrangements. Nature, 1986, 319, 28-33.	13.7	152
66	The inducible cytotoxic T-lymphocyte-associated gene transcript CTLA-1 sequence and gene localization to mouse chromosome 14. Nature, 1986, 322, 268-271.	13.7	194
67	Interleukin 1 and protein kinase C activator are dissimilar in their effects on Il-2 receptor expression and Il-2 secretion by T lymphocytes. Cellular Immunology, 1986, 103, 365-374.	1.4	3
68	Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature, 1985, 313, 318-320.	13.7	757
69	Lysis of hybridoma cells bearing anti-clonotypic surface immunoglobulin by clonotype-expressing alloreactive cytotoxic T cells. European Journal of Immunology, 1985, 15, 1029-1033.	1.6	22
70	Lymphoid Cell Surface Interaction Structures Detected Using Cytolysis-Inhibiting Monoclonal Antibodies. Immunological Reviews, 1982, 68, 5-42.	2.8	146